Evidence map›Paper›PMID 38925803›Full record

Trial reportBMJ (Clinical research ed.)2024

Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial.

Jiejie Li, Xia Meng, Fu-Dong Shi, Jing Jing, Hong-Qiu Gu, Aoming Jin, Yong Jiang, Hao Li, S Claiborne Johnston, Graeme J Hankey and 28 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ (Clinical research ed.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05439356 (Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack), which is not on this map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05439356 phase3completednot on this map

Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)

TypeinterventionalSponsorBeijing Tiantan HospitalRan2022 to 2024Enrolled8,343ConditionsIschemic Stroke, TIAArmsColchicine, Placebo colchicine
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Efficacy of Colchicine for Prevention of Stroke and Adverse Cardiovascular Events: A Meta-analysis of 16 Randomized Controlled Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Jiejie LiDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xia MengDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Fu-Dong ShiDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jing JingDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hong-Qiu GuDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Aoming JinDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yong JiangDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hao LiDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
S Claiborne JohnstonDepartment of Neurology, University of California, San Francisco, CA, USA.
Graeme J HankeyMedical School, University of Western Australia, Perth, WA, Australia.
J Donald EastonDepartment of Neurology, University of California, San Francisco, CA, USA.
Liguo ChangDepartment of Neurology, Liaocheng Third People's Hospital, Shandong, China.
Penglai ShiDepartment of Neurology, Yantai Penglai Traditional Chinese Medicine Hospital, Shandong, China.
Lihua WangDepartment of Neurology, The Second Affiliated Hospital of Harbin Medical University, Heilongjiang, China yongjunwang@ncrcnd.org.cn.
Xianbo ZhuangDepartment of Neurology, Liaocheng People's Hospital, Shandong, China.
Haitao LiDepartment of Neurology, The People's Hospital of Qihe County, Shandong, China.
Yingzhuo ZangDepartment of Neurology, Qinghe People's Hospital, Hebei, China.
Jianling ZhangDepartment of Neurology, The Fourth People's Hospital of Hengshui, Hebei, China.
Zengqiang SunDepartment of Neurology, Zibo Municipal Hospital, Shandong, China.
Dongqi LiuDepartment of Neurology, Hejian People's Hospital, Hebei, China.
Ying LiDepartment of Neurology, Suixian Chinese Medicine Hospital, Henan, China.
Hongqin YangDepartment of Neurology, Jiyuan Hospital of TCM, Henan, China.
Jinguo ZhaoDepartment of Neurology, Weihai Wendeng District People's Hospital, Shandong, China.
Weiran YuDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Anxin WangDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China yongjunwang@ncrcnd.org.cn.
Yuesong PanDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jinxi LinDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuewei XieDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wei-Na JinDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Shuya LiDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Siying NiuDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yilong WangDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China yongjunwang@ncrcnd.org.cn.
Xingquan ZhaoDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zixiao LiDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Liping LiuDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Huaguang ZhengDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yongjun WangDepartment of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China yongjunwang@ncrcnd.org.cn.ORCID 0000-0002-9976-2341
CHANCE-3 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the efficacy and safety of colchicine versus placebo on reducing the risk of subsequent stroke after high risk non-cardioembolic ischaemic stroke or transient ischaemic attack within the first three months of symptom onset (CHANCE-3).

designMulticentre, double blind, randomised, placebo controlled trial.

setting244 hospitals in China between 11 August 2022 and 13 April 2023.

participants8343 patients aged 40 years of age or older with a minor-to-moderate ischaemic stroke or transient ischaemic attack and a high sensitivity C-reactive protein ≥2 mg/L were enrolled.

interventionsPatients were randomly assigned 1:1 within 24 h of symptom onset to receive colchicine (0.5 mg twice daily on days 1-3, followed by 0.5 mg daily thereafter) or placebo for 90 days.

main outcome measuresThe primary efficacy outcome was any new stroke within 90 days after randomisation. The primary safety outcome was any serious adverse event during the treatment period. All efficacy and safety analyses were by intention to treat.

results4176 patients were assigned to the colchicine group and 4167 were assigned to the placebo group. Stroke occurred within 90 days in 264 patients (6.3%) in the colchicine group and 270 patients (6.5%) in the placebo group (hazard ratio 0.98 (95% confidence interval 0.83 to 1.16); P=0.79). Any serious adverse event was observed in 91 (2.2%) patients in the colchicine group and 88 (2.1%) in the placebo group (P=0.83).

conclusionsThe study did not provide evidence that low-dose colchicine could reduce the risk of subsequent stroke within 90 days as compared with placebo among patients with acute non-cardioembolic minor-to-moderate ischaemic stroke or transient ischaemic attack and a high sensitivity C-reactive protein ≥2 mg/L.

trial registrationClinicalTrials.gov, NCT05439356.

Indexed as

ColchicineIschemic Attack, TransientIschemic StrokeAdultAgedChinaC-Reactive ProteinDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeColchicineC-Reactive Protein

Identifiers

PMID38925803
PMCPMC11200154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.